Targeted therapy and immunotherapy of esophageal cancer / 国际肿瘤学杂志

ABSTRACT

Esophageal cancer is a complex digestive tract cancer. Currently, the study of radiotherapy and chemotherapy for non-surgical esophageal cancer has reached the bottleneck. In recent years, with the in-depth study of tumor signal pathway related targets and immunotherapy, tumor treatment methods are becoming more and more diversified. At present, research shows that a variety of gene targets and immune receptors are related to esophageal cancer, including epidermal growth factor receptor, vascular endothelial growth factor, human epidermal growth factor receptor 2, programmed death-1/programmed death ligand-1, etc. In addition, tumor vaccine and adoptive cell therapy are also being studied. These factors contribute to the individualized and accurate treatment of esophageal cancer and improve survival rate and local control rate.